These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20069648)

  • 21. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
    Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA
    J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
    Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
    Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
    Evans MJ; von Hahn T; Tscherne DM; Syder AJ; Panis M; Wölk B; Hatziioannou T; McKeating JA; Bieniasz PD; Rice CM
    Nature; 2007 Apr; 446(7137):801-5. PubMed ID: 17325668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.
    Farquhar MJ; Harris HJ; Diskar M; Jones S; Mee CJ; Nielsen SU; Brimacombe CL; Molina S; Toms GL; Maurel P; Howl J; Herberg FW; van Ijzendoorn SC; Balfe P; McKeating JA
    J Virol; 2008 Sep; 82(17):8797-811. PubMed ID: 18579596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
    Tawar RG; Colpitts CC; Timm J; Fehm T; Roggendorf M; Meisel H; Meyer N; Habersetzer F; Cosset FL; Berg T; Zeisel MB; Baumert TF
    Hepatology; 2015 Sep; 62(3):726-36. PubMed ID: 26010076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
    Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
    J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.
    Davis C; Harris HJ; Hu K; Drummer HE; McKeating JA; Mullins JG; Balfe P
    Cell Microbiol; 2012 Dec; 14(12):1892-903. PubMed ID: 22897233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
    Witteveldt J; Evans MJ; Bitzegeio J; Koutsoudakis G; Owsianka AM; Angus AG; Keck ZY; Foung SK; Pietschmann T; Rice CM; Patel AH
    J Gen Virol; 2009 Jan; 90(Pt 1):48-58. PubMed ID: 19088272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.
    Ploss A; Evans MJ; Gaysinskaya VA; Panis M; You H; de Jong YP; Rice CM
    Nature; 2009 Feb; 457(7231):882-6. PubMed ID: 19182773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
    Zeisel MB; Koutsoudakis G; Schnober EK; Haberstroh A; Blum HE; Cosset FL; Wakita T; Jaeck D; Doffoel M; Royer C; Soulier E; Schvoerer E; Schuster C; Stoll-Keller F; Bartenschlager R; Pietschmann T; Barth H; Baumert TF
    Hepatology; 2007 Dec; 46(6):1722-31. PubMed ID: 18000990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus entry and the tetraspanin CD81.
    Farquhar MJ; Harris HJ; McKeating JA
    Biochem Soc Trans; 2011 Apr; 39(2):532-6. PubMed ID: 21428934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection.
    Meyer K; Kwon YC; Liu S; Hagedorn CH; Ray RB; Ray R
    Sci Rep; 2015 Mar; 5():9012. PubMed ID: 25757571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.
    Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B
    PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
    Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
    Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.
    Rocha-Perugini V; Lavie M; Delgrange D; Canton J; Pillez A; Potel J; Lecoeur C; Rubinstein E; Dubuisson J; Wychowski C; Cocquerel L
    BMC Microbiol; 2009 May; 9():111. PubMed ID: 19476617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.